Mostrar el registro sencillo del documento

dc.rights.licenseAtribución-NoComercial 4.0 Internacional
dc.contributor.advisorVarela- Ramírez, Rodolfo
dc.contributor.authorCerquera Cleves, Diana María
dc.date.accessioned2020-02-17T14:39:45Z
dc.date.available2020-02-17T14:39:45Z
dc.date.issued2020-01-29
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/75617
dc.description.abstractIntroducción y objetivo: La incidencia del cáncer renal ha aumentado en los últimos años, se ha demostrado que hasta el 30% de los pacientes que son sometidos a nefrectomía con intención curativa presentan progresión. El Objetivo de este estudio es determinar los factores de riesgo para progresión a enfermedad metastásica en pacientes con cáncer renal localizados llevada a nefrectomía radical. Metodología: Estudio retrospectivo de cohortes en pacientes con cáncer renal manejados con nefrectomía radical que tuvieron seguimiento mínimo de 3 años en el Instituto Nacional de Cancerología (INC), Se realizarán análisis univariados y multivariados por medio del modelo de regresión de Cox para determinar Hazard Ratios (HR) para progresión metastásica con las variables clínicas y patológicas a evaluar. Resultados: Se incluyeron 215 pacientes en el estudio, las variables relacionadas con el aumento en la velocidad de aparición de metástasis a los 3 años fueron el género masculino, pT3 y pT4, bordes positivos, presencia de diferenciación sarcomatoide, tamaño ≥ 10 cms, el abordaje quirúrgico laparoscópico, el Fuhrman 3 y 4 y el subtipo de células claras. Sin embargo, en el análisis multivariado no se evidenciaron diferencias en la variante de histología y tamaño. Conclusiones: Existen factores de riesgo que pueden aumentar la probabilidad de recaída metastasica en pacientes con neoplasia renal localizada manejada con nefrectomía radical con intención curativa, por este motivo es posible que requieran de un protocolo de seguimiento más estrecho para su detección temprana y manejo oportuno.
dc.description.abstractIntroduction and objective: The incidence of renal cancer has increased in recent years, has shown that up to 30% of patients who have ever undergone a nephrectomy with curative intent have progression. The objective of this study is to determine the risk factors for the progression to metastatic disease in patients with localized renal cancer managed with radical nephrectomy. Methodology: Retrospective cohort study in patient with renal cancer managed with radical nephrectomy who had a minimum follow-up of 3 years at the National Cancer Institute (INC). A univariate and multivariate analysis was performed using the Cox regression model to establish the risk ratios (HR) for metastatic progression with clinical and pathological variables under evaluation. Results: 215 patient were included in the study, the variables related to the increase in the speed pf metastasis at 3 years were male, pT3 y pT4, positive edges, presence of sarcomatoid differentiation, size ≥ 10 cm,laparoscopic surgery surgical approach, Fuhrman 3 and 4, and the clear cell subtype. However, in the multivariate analysis no differences were found in histology and size variant. Conclusions: There are risk factors that can increase the probability of metastatic relapse in patients with localized renal neoplasia managed with radical nephrectomy with curative intent. For this reason, it is possible that it will require a close follow-up protocol for its early detection and timely treatment.
dc.format.extent36
dc.format.mimetypeapplication/pdf
dc.language.isospa
dc.rightsDerechos reservados - Universidad Nacional de Colombia
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subject.ddcMedicina y salud
dc.titleEvaluación de factores de riesgo relacionados con el desarrollo de metástasis en pacientes con cáncer renal en el Instituto Nacional de Cancerología
dc.title.alternativeEvaluation of risk factors related to the development of metastases in patients with renal cancer managed at the National Cancer Institute
dc.typeDocumento de trabajo
dc.rights.spaAcceso abierto
dc.description.additionalEspecialista en Urología. Línea de investigación: Urología Oncológica.
dc.type.driverinfo:eu-repo/semantics/workingPaper
dc.type.versioninfo:eu-repo/semantics/acceptedVersion
dc.contributor.researchgroupGrupo de investigación e innovación en Urología - Universidad Nacional de Colombia
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotá
dc.relation.references1.Williamson TJ, Pearson JR, Ischia J et al. Guideline of guidelines: follow-up after nephrectomy for renal cell carcinoma. BJU Int.2016;117(4):555-62.2.GuL, Li H, Wang Z y cols. A systematic review and meta-analysis of clinicopathologic factors linked to oncologic outcomes for renal cell carcinoma with tumor thrombus treated by radical nephrectomy with thrombectomy. Cancer Treat Rev. 2018;21;69:112–20.3.Medina-Rico M, Ramos HL, Lobo M y cols. Epidemiology of renal cancer in developing countries: Review of the literature. Can Urol Assoc J. 2018;12(3):E154–62.4.Capogrosso y cols. Follow-up After Treatment for Renal Cell Carcinoma: The Evidence Beyond the Guidelines. Eur Urol. 2016;1(3):273-815.Tyson MD, Chang SS. Optimal Surveillance Strategies After Surgery for Renal Cell Carcinoma. J Natl Compr Canc Netw. 2017;15(6):835–406.Dabestani S, Marconi L, Kuusk T y cols. Follow-up after curative treatment of localised renal cell carcinoma. World J Urol. 2018;16: 1-77.Dabestani S, Beisland C, Stewart GD. Long-term Outcomes of Follow-up for Initial y cols. Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis. Eur Urol Focus. 2018;S2405-4569(18): 30072-58.Kuijpers YAM, Meijer RP, Jonges GN y cols. Potentially curable recurrent disease after surgically managed non-metastatic renal cell carcinoma in low-, intermediate-and high-risk patients. World J Urol. 2016;34(8):1073–9.9.Klatte T, Rossi SH, Stewart GD. Prognostic factors and prognostic models for renal cell carcinoma: a literature review. World J Urol. 2018; 30: 2309-410.Kim SH, Park B, Hwang EC et al. Retrospective Multicenter Long-Term Follow-up Analysis of Prognostic Risk Factors for Recurrence-Free, Metastasis-Free, Cancer-Specific, and Overall Survival After Curative Nephrectomy in Non-metastatic Renal Cell Carcinoma. Front. Oncol.2019; 9:859 11.Volpe A, Patard JJ. Prognostic factors in renal cell carcinoma. World J Urol. 2010;28(3):319–27.12.Capitanio U,Cloutier V, Zini L y cols. A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study. BJU Int. 2009;103(11):1496–500.13.Volpe A, Novara G, Antonelli A y cols. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series. BJU Int. 2012;110(1):76–83.14.Leibovich BC, Lohse CM, ChevilleJ.C. et al. Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery. European Urol. 2018; 73(5), 772–78015.Zhang L, Wu B, Zha Z y cols. The prognostic value and clinicopathological features of sarcomatoid differentiation in patients with renal cell carcinoma: a systematic review and meta-analysis. Cancer Manag Res. 2018;10:1687–703.16.Abu-Ghanem et al.Positive surgical margin following radical nephrectomy is an independent predictor of local recurrence and disease-specific survival. World Jour of Surg Oncol. 2017; 5:19317.Kang HW, Seo SP,Kim WT et al. Impact of Young Age at Diagnosis on Survival in Patients with Surgically Treated Renal Cell Carcinoma: A Multicenter Study. J Korean Med Sci. 2016; 31: 1976-1982. 18.Laird A,Choy KC,Delaney H. et al. Matched pair analysis of laparoscopic versus open radical nephrectomy for the treatment of T3renal cell carcinoma. World J Urol.2015 Jan;33(1):25-3219.Radadia KD,et al. Accuracy of clinical nodal staging and factors associated with receipt oflymphnode dissection at the time of surgery for nonmetastaticrenal cell carcinoma. Urol Oncol.2019 Sep;37(9):577.e17-577.e25.20.Lee HW, et al.Diagnostic and Prognostic Significance of Radiologic Node-positive Renal Cell Carcinoma in the Absence of Distant Metastases: A Retrospective Analysis of Patients Undergoing Nephrectomy and Lymph Node Dissection.J Korean Med Sci. 2015;30(9):1321–1327. 21.Delahunt B, Egevad L, Samaratunga H, Martignoni G, Nacey JN, Srigley JR. Gleason and Fuhrman no longer make the grade. Histopathology. 2016;68(4):475–81 22.Bex A, Jonasch E, Kirkali Z, et al. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Eur Urol 2010;58:819–28.
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.subject.proposalCancer
dc.subject.proposalCáncer
dc.subject.proposalRenal
dc.subject.proposalRenal
dc.subject.proposalMetástasis
dc.subject.proposalMetastasis
dc.subject.proposalRiesgo
dc.subject.proposalRisk factors
dc.subject.proposalNephrectomy
dc.subject.proposalFactores
dc.subject.proposalNefrectomía
dc.type.coarhttp://purl.org/coar/resource_type/c_8042
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.contentText
dc.type.redcolhttp://purl.org/redcol/resource_type/WP
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2


Archivos en el documento

Thumbnail

Este documento aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del documento

Atribución-NoComercial 4.0 InternacionalEsta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial 4.0.Este documento ha sido depositado por parte de el(los) autor(es) bajo la siguiente constancia de depósito